Literature DB >> 33117804

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy.

Guo Li1, Yuan Tian1,2, Wei-Guo Zhu1,2.   

Abstract

Genetic mutations and abnormal gene regulation are key mechanisms underlying tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores, represent the basic units of chromatin. The fifth amino group (Nε) of histone lysine residues is a common site for post-translational modifications (PTMs), and of these, acetylation is the second most common. Histone acetylation is modulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), and is involved in the regulation of gene expression. Over the past two decades, numerous studies characterizing HDACs and HDAC inhibitors (HDACi) have provided novel and exciting insights concerning their underlying biological mechanisms and potential anti-cancer treatments. In this review, we detail the diverse structures of HDACs and their underlying biological functions, including transcriptional regulation, metabolism, angiogenesis, DNA damage response, cell cycle, apoptosis, protein degradation, immunity and other several physiological processes. We also highlight potential avenues to use HDACi as novel, precision cancer treatments.
Copyright © 2020 Li, Tian and Zhu.

Entities:  

Keywords:  HDAC; HDAC inhibitors; HDAC sequence; cancer therapy; histone modification

Year:  2020        PMID: 33117804      PMCID: PMC7552186          DOI: 10.3389/fcell.2020.576946

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  517 in total

Review 1.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.

Authors:  Katrina J Falkenberg; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2014-08-18       Impact factor: 84.694

2.  DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters.

Authors:  K D Robertson; S Ait-Si-Ali; T Yokochi; P A Wade; P L Jones; A P Wolffe
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

3.  Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes.

Authors:  M S Kim; H J Kwon; Y M Lee; J H Baek; J E Jang; S W Lee; E J Moon; H S Kim; S K Lee; H Y Chung; C W Kim; K W Kim
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

4.  SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.

Authors:  Matthew D Hirschey; Tadahiro Shimazu; Eric Goetzman; Enxuan Jing; Bjoern Schwer; David B Lombard; Carrie A Grueter; Charles Harris; Sudha Biddinger; Olga R Ilkayeva; Robert D Stevens; Yu Li; Asish K Saha; Neil B Ruderman; James R Bain; Christopher B Newgard; Robert V Farese; Frederick W Alt; C Ronald Kahn; Eric Verdin
Journal:  Nature       Date:  2010-03-04       Impact factor: 49.962

5.  The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.

Authors:  A Newbold; J M Salmon; B P Martin; K Stanley; R W Johnstone
Journal:  Oncogene       Date:  2013-12-02       Impact factor: 9.867

6.  Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery.

Authors:  Celeste B Greer; Yoshiaki Tanaka; Yoon Jung Kim; Peng Xie; Michael Q Zhang; In-Hyun Park; Tae Hoon Kim
Journal:  Cell Rep       Date:  2015-11-05       Impact factor: 9.423

7.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316

8.  Epigenetic therapy inhibits metastases by disrupting premetastatic niches.

Authors:  Zhihao Lu; Jianling Zou; Shuang Li; Michael J Topper; Yong Tao; Hao Zhang; Xi Jiao; Wenbing Xie; Xiangqian Kong; Michelle Vaz; Huili Li; Yi Cai; Limin Xia; Peng Huang; Kristen Rodgers; Beverly Lee; Joanne B Riemer; Chi-Ping Day; Ray-Whay Chiu Yen; Ying Cui; Yujiao Wang; Yanni Wang; Weiqiang Zhang; Hariharan Easwaran; Alicia Hulbert; KiBem Kim; Rosalyn A Juergens; Stephen C Yang; Richard J Battafarano; Errol L Bush; Stephen R Broderick; Stephen M Cattaneo; Julie R Brahmer; Charles M Rudin; John Wrangle; Yuping Mei; Young J Kim; Bin Zhang; Ken Kang-Hsin Wang; Patrick M Forde; Joseph B Margolick; Barry D Nelkin; Cynthia A Zahnow; Drew M Pardoll; Franck Housseau; Stephen B Baylin; Lin Shen; Malcolm V Brock
Journal:  Nature       Date:  2020-02-26       Impact factor: 69.504

9.  SIRT7-mediated ATM deacetylation is essential for its deactivation and DNA damage repair.

Authors:  Ming Tang; Zhiming Li; Chaohua Zhang; Xiaopeng Lu; Bo Tu; Ziyang Cao; Yinglu Li; Yongcan Chen; Lu Jiang; Hui Wang; Lina Wang; Jiadong Wang; Baohua Liu; Xingzhi Xu; Haiying Wang; Wei-Guo Zhu
Journal:  Sci Adv       Date:  2019-03-27       Impact factor: 14.136

10.  Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia.

Authors:  Cornelis M van Tilburg; Till Milde; Ruth Witt; Jonas Ecker; Thomas Hielscher; Angelika Seitz; Jens-Peter Schenk; Juliane L Buhl; Dennis Riehl; Michael C Frühwald; Arnulf Pekrun; Claudia Rossig; Regina Wieland; Christian Flotho; Uwe Kordes; Bernd Gruhn; Thorsten Simon; Christin Linderkamp; Felix Sahm; Lenka Taylor; Angelika Freitag; Jürgen Burhenne; Kathrin I Foerster; Andreas D Meid; Stefan M Pfister; Irini Karapanagiotou-Schenkel; Olaf Witt
Journal:  Clin Epigenetics       Date:  2019-12-10       Impact factor: 6.551

View more
  42 in total

Review 1.  The role of histone deacetylase 3 in breast cancer.

Authors:  Rezgar Rahbari; Yousef Rasmi; Mohammad Hassan Khadem-Ansari; Mohammad Abdi
Journal:  Med Oncol       Date:  2022-05-17       Impact factor: 3.064

2.  Identification of histone deacetylase 10 (HDAC10) inhibitors that modulate autophagy in transformed cells.

Authors:  Patrik Zeyen; Yanira Zeyn; Daniel Herp; Fereshteh Mahmoudi; Talha Z Yesiloglu; Frank Erdmann; Matthias Schmidt; Dina Robaa; Christophe Romier; Johannes Ridinger; Corey J Herbst-Gervasoni; David W Christianson; Ina Oehme; Manfred Jung; Oliver H Krämer; Wolfgang Sippl
Journal:  Eur J Med Chem       Date:  2022-03-11       Impact factor: 6.514

3.  Expression patterns and therapeutic implications of histone deacetylase-1 across carcinomas: a comprehensive molecular docking and MD simulation study.

Authors:  Bader Alshehri
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 4.  Epigenetic Regulation of Inflammatory Signaling and Inflammation-Induced Cancer.

Authors:  Shawn Ying Xuan Tan; Jieqiong Zhang; Wee-Wei Tee
Journal:  Front Cell Dev Biol       Date:  2022-06-08

Review 5.  The role of histone modifications: from neurodevelopment to neurodiseases.

Authors:  Jisu Park; Kyubin Lee; Kyunghwan Kim; Sun-Ju Yi
Journal:  Signal Transduct Target Ther       Date:  2022-07-06

6.  High HDAC5 expression correlates with a poor prognosis and the tumor immune microenvironment in gastric cancer.

Authors:  Li Yuan; Can Hu; Pengcheng Yu; Zhehan Bao; Yuhang Xia; Bo Zhang; Yi Wang
Journal:  Ann Transl Med       Date:  2022-09

7.  Patient-Derived Organoids for In Vivo Validation of In Vitro Data.

Authors:  Said Kdimati; Florian Bürtin; Michael Linnebacher; Christina Susanne Mullins
Journal:  Methods Mol Biol       Date:  2023

Review 8.  Discovering the landscape of protein modifications.

Authors:  E Keith Keenan; Derek K Zachman; Matthew D Hirschey
Journal:  Mol Cell       Date:  2021-04-01       Impact factor: 17.970

Review 9.  What Are the Potential Roles of Nuclear Perlecan and Other Heparan Sulphate Proteoglycans in the Normal and Malignant Phenotype.

Authors:  Anthony J Hayes; James Melrose
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

10.  Expression and prognostic analyses of HDACs in human gastric cancer based on bioinformatic analysis.

Authors:  Luting Chen; Yuchang Fei; Yurong Zhao; Quan Chen; Peifeng Chen; Lei Pan
Journal:  Medicine (Baltimore)       Date:  2021-07-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.